Nestle patents ingredients targeting neurological and weight problems

Meroterpenoids and age-tailored infant formula are two technologies that Nestle has developed and patented in 2019

Nestle has filed two patents for nutraceutical products recently. The first covers meroterpenoid compounds that promote lactate secretion for neurological benefits. The second covers tailored infant formula aimed at preventing adulthood obesity.

Meroterpenoids

The global patent for meroterpenoid compounds was filed in September 2018, and published in March 2019.

The patent abstract said: “The present invention relates to a compound, in particular to a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention and a food or feed supplement is also provided.”

Though the main function was stated as for prevention and treatment of neurological disorders, other disorders were stated in the wider description. These included diabetes-related disorders and autoimmune diseases.

Meroterpenoids can be derived from fungi and can display quite diverse structures, with a wide range of biological properties.

Age-tailored formula for infants

The global patent for age-tailored formulas was filed in November 2018 and published in May 2019.

The formulas address weight management following the idea that calorific intake in early years can impact weight and consequent issues in later life. This long-term need has been shown in animals with experiments illustrating that giving suboptimal energy intake in early years affected weight gain in later life.

The patent abstract said: “An array of nutritional compositions for infants and/or young children is proposed. Each composition of this array is targeted at a specific age of the infant/young child and it is formulated to prevent suboptimal body composition of the subject (especially in terms of fat mass and/or fat-free mass). By preventing suboptimal body composition of the arrays of the invention of a diuretic system and the treatment of diabetes, overweight, diabetes and diabetes-related conditions, and/or cardiovascular diseases.”

Companies